Voyager Therapeutics Promotes Jeff Goater To Senior Vice President, Finance And Business Development

Cambridge, Mass., April 28, 2015 – Voyager Therapeutics, a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the appointment of Jeff Goater, former vice president of business development, to senior vice president, finance and business development. In this new role, Mr. Goater will be responsible for overseeing finance, business development, and investor and public relations activities across the company.

"Jeff's promotion to senior vice president reflects his superior leadership and continued success identifying strategic growth opportunities for the company," said Steven Paul, M.D., president and CEO of Voyager Therapeutics. "Jeff has been an integral part of the leadership team since Voyager's inception, playing an instrumental role in our strategic collaboration with Genzyme and our recent $60 million Series B financing. We will continue to utilize his deep business development expertise to accelerate our gene therapy pipeline and bring forward life-changing therapies for patients with CNS diseases."

Mr. Goater has served as vice president of business development since the launch of Voyager in 2014, bringing to the company more than 15 years of business development and financial experience in the biotech industry. Prior to Voyager, he spent nearly a decade on Wall Street, most recently as a managing director at Evercore Partners, focused on strategic advisory in the life sciences sector. While at Evercore, Mr. Goater advised on more than $100 billion in M&A and licensing transactions. He began his Wall Street career as an equity research analyst at Cowen and Company, covering the biopharmaceutical sector. Prior to Cowen, Mr. Goater worked in biotech business development and began his career as a research scientist in the fields of musculoskeletal biology and gene therapy. Mr. Goater holds a B.A. in biology, an M.S. in pathology/molecular medicine, an M.S. in microbiology/immunology and an M.B.A., all from the University of Rochester.

About Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing and delivery techniques, as well as process development and production. The company's pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson's disease, a monogenic form of amyotrophic lateral sclerosis (ALS), Friedreich's ataxia and Huntington's disease. Voyager has broad strategic collaborations with Genzyme, a Sanofi company, and the University of Massachusetts Medical School (UMMS). Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
 

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.